Created at	Source	Raw Value	Validated value
Feb. 15, 2024, 4 a.m.	usa	Percentage of Participants With Solicited Injection-Site Adverse Events (AEs) Among Participants Administered V110;Percentage of Participants With Solicited Injection-Site Adverse Events Among Participants Administered V114;Percentage of Participants With Solicited Systemic AEs Among Participants Administered V110;Percentage of Participants With Solicited Systemic AEs Among Participants Administered V114;Percentage of Participants With Vaccine-Related SAEs Among Participants Administered V114;Percentage of Participants With Vaccine-Related Serious AEs (SAEs) Among Participants Administered V110;SARS-CoV-2-specific Binding Antibody (bAb) GMT in Participants Administered Either V110 or V114;Serotype-specific OPA GMT in Participants Administered V114;Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) in Participants Administered V110	Percentage of Participants With Solicited Injection-Site Adverse Events (AEs) Among Participants Administered V110;Percentage of Participants With Solicited Injection-Site Adverse Events Among Participants Administered V114;Percentage of Participants With Solicited Systemic AEs Among Participants Administered V110;Percentage of Participants With Solicited Systemic AEs Among Participants Administered V114;Percentage of Participants With Vaccine-Related SAEs Among Participants Administered V114;Percentage of Participants With Vaccine-Related Serious AEs (SAEs) Among Participants Administered V110;SARS-CoV-2-specific Binding Antibody (bAb) GMT in Participants Administered Either V110 or V114;Serotype-specific OPA GMT in Participants Administered V114;Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) in Participants Administered V110
Dec. 17, 2021, 2 a.m.	usa	OPA GMT with V114;Opsonophagocytic activity (OPA) Geometric mean titer (GMT) with V110;Participants with solicited injection-site adverse events (AEs);Participants with solicited systemic AEs;Participants with vaccine-related serious AEs (SAEs);SARS-CoV-2-specific binding antibody (bAb) GMT	OPA GMT with V114;Opsonophagocytic activity (OPA) Geometric mean titer (GMT) with V110;Participants with solicited injection-site adverse events (AEs);Participants with solicited systemic AEs;Participants with vaccine-related serious AEs (SAEs);SARS-CoV-2-specific binding antibody (bAb) GMT